Mental Illness Archives - Purablis-Medicinal Tinctures with CBD, THCA and THC

Mental Illness Marijuana Studies and

Mental Illness Cannabis Research

09/28/2018

Author(s): Michelle Roche and David P Finn.

The CB2 receptor as a possible target for the treatment of neuroinflammatory and neurodegenerative disorders. View study

09/28/2018

Author(s): A.W. Zuardi2, J.A.S. Crippa2, J.E.C. Hallak2, F.A. Moreira and F.S. Guimarães.

CBD could have anxiolytic (calming) and / or antipsychotic applications in patients. View study

09/28/2018

Author(s): C.D. Schubartc, I.E.C. Sommera, P. Fusar-Polib, L. de Wittea,R.S. Kahnc, M.P.M. Boksa,n.

A review that concisely describes the role of the endocannabinoid system in the development of psychosis and provides an overview of several currently available studies on the antipsychotic properties of CBD. View study

09/28/2018

Author(s): Leonora E Long, Daniel T Malone and David A Taylor.

Cannabidiol acts as an agonist of the vanilloid channel 1 in the transient receptor potential family (TRPV1) and also to inhibit the hydrolysis and cellular uptake of the endogenous cannabinoid anandamide. Cannabidiol also has potential as an antipsychotic. View study

09/28/2018

Author(s): Lydie J Morel, Bruno Giros, and Vale´rie Dauge´,.

THC acts as a homeostatic modifier that worsens the reward effects of morphine in naive animal models, but which would improve deficits in maternal models. This suggests the use of cannabis individuals subjected to an adverse postnatal environment. View study

09/28/2018

Author(s): Michelle Roche and David P Finn.

The CB2 receptor as a possible target for the treatment of neuroinflammatory and neurodegenerative disorders. View study

09/28/2018

Author(s): A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira and F.S. Guimarães.

CBD could have anxiolytic (calming) and / or antipsychotic applications in patients. View study

09/28/2018

Author(s): Yanhua Ren, John Whittard, Alejandro Higuera-Matas, Claudia V. Morris, and Yasmin L. Hurd.

Using an animal model, this study examines the effects of CBD on the self-administration of heroin and concludes that it can be used effectively in patients with heroin addiction. View study

09/28/2018

Author(s): C.D. Schubartc, I.E.C. Sommera, P. Fusar-Polib, L. de Wittea,R.S. Kahnc, M.P.M. Boksa.

A review that concisely describes the role of the endocannabinoid system in the development of psychosis and provides an overview of several currently available studies on the antipsychotic properties of CBD. View study

09/28/2018

Author(s): Alline C. Campos, Manoela V. Fogac, Andreza B. Sonegoa, Francisco S. Guimarães.

The neuroprotective properties of cannabidiol seem to depend on several cannabinoid-dependent and independent mechanisms. Preclinical evidence clearly indicate that cannabidiol represents a new opportunity for the treatment of several brain disorders (such as neurodegenerative and neuropsychiatric) where neuronal loss or damage plays a significant role. View study

09/28/2018

Author(s): Leonora E Long, Daniel T Malone and David A Taylor.

Cannabidiol acts as an agonist of the vanilloid channel 1 in the transient receptor potential family (TRPV1) and also to inhibit the hydrolysis and cellular uptake of the endogenous cannabinoid anandamide. Cannabidiol also has potential as an antipsychotic. View study

09/28/2018

Author(s): Amanda Reiman.

This study was conducted based on data collected in an anonymous survey to examine the use of alcohol and drugs, and the occurrence of substitution among medicinal cannabis patients. It was found that the reasons for the substitution were: fewer adverse side effects (65%), better management of symptoms (57%) and less potential for abstinence (34%) with cannabis. As a result of this study it was found that medicinal cannabis patients have been participating in the substitution using cannabis as an alternative to alcohol, prescriptions and illicit drugs. View study